Targeting the tumor microenvironment (Stroma) for treatment of metastasis

Angiogenesis: An Integrative Approach From Science to Medicine

Volumn , Issue , 2008, Pages 259-270

  Fidler, Isaiah J ^a   Baker, Cheryl Hunt ^a   Yokoi, Kenji ^a   Kuwai, Toshio ^a   Nakamura, Toru ^a   Nilsson, Monique ^a   Busby, J Erik ^a   Langley, Robert R ^a   Kim, Sun Jin ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

organ specific metastasis; pathogenesis of metastasis; tumor microenvironment

Indexed keywords

EID: 84878755166     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-71518-6_23     Document Type: Chapter

References (117)

1. Fidler IJ. Critical factors in the biology of human cancer metastasis: twenty-eighth GHA Clowes memorial award lecture. Cancer Res 1990; 50:6130-38.
2. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited (Timeline). Nat. Rev. Cancer 2003; 3:453-8.
3. rd edition. Philadelphia, PA: Elsevier Science, 2004:59-79.
4. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991; 64:327-36.
5. Weiss L. Metastasis of cancer: a conceptual history from antiquity to the 1990s. Cancer Metastasis Rev 2000; 19:193-400.
6. 125I-5-iodo-2'-deoxyuridine. J Natl Cancer Inst 1970; 45:773-82.
7. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889; 1:571-3.
8. Hart IR, Fidler IJ. Role of organ selectivity in the determination of metastatic patterns of the B16 melanoma. Cancer Res 1980; 40:2281-7.
9. Tarin D, Price JE, Kettlewell MG, et al. Mechanisms of human tumor metastasis studied in patients with peritoneovenous shunts. Cancer Res 1984; 44:3584-92.
10. Schackert G, Fidler IJ. Site-specific metastasis of moue melanomas and a fibrosarcoma in the brain or meninges of syngeneic animals. Cancer Res 1988; 48:3478-84.
11. Schackert G, Price JE, Zhang RD, et al. Regional growth of different human melanoma as metastasis in the brain of nude mice. Am J Pathol 1990; 136:95-102.
12. b-tsA58 mice for studies of angiogenesis and metastasis. Cancer Res 2003; 63:2971-6.
13. Langley RR, Fan D, Tsan RZ, et al. 2004. Activation of the plateletderived growth factor receptor enhances survival of murine bone endothelial cells. Cancer Res (Adv in Brief) 2004; 64: 3727-30.
14. Fidler IJ. The organ microenvironment and cancer metastasis (Review). Differentiation 2002; 70:498-505.
15. Fidler IJ, Yano S, Zhang RD, et al. The seed and soil hypothesis: vascularization and brain metastases (Personal View). Lancet Oncol 2002; 3:53-7.
16. Folkman J. Angiogenesis in cancer, vascular, rheumatoid, and other diseases. Nat Med 1995; 1:27-31.
17. Singh RK, Bucana CD, Gutman M, et al. Organ site-dependent expression of basic fibroblast growth factor in human renal cell carcinoma cells. Am J Pathol 1994; 145:365-74.
18. Singh RK, Gutman M, Bucana CD, et al. Interferons alpha and beta downregulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci USA 1995; 92: 4562-6.
19. Singh RK, Gutman M, Radinsky R, et al. Expression of inter-leukin 8 correlates with the metastatic potential of human melanoma cells in nude mice. Cancer Res 1994; 54:3242-7.
20. Nilsson MB, Langley RR, Fidler IJ. Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cyto-kine. Cancer Res 2005; 65:10794-800.
21. Nanus DM, Schmitz-Drager BJ, Motzer RJ, et al. Expression of basic fibroblast growth factor in primary human renal tumors: correlation with poor survival. J Natl Cancer Inst 1994; 85: 1587-99.
22. Nguyen M, Watanabe H, Budson AE, et al. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 1994; 86:356-61.
23. Leek RD, Harris AL, Lewis CE. Cytokine networks in solid human tumors: regulation of angiogenesis. J Leukoc Biol 1994; 56:423-35.
24. Gutman M, Singh RK, Bucana CD, et al. Regulation of IL-8 expression in human melanoma cells by the organ environment. Cancer Res 1995; 55:2470-5.
25. Hirano T, Yasukawa K, Harada H, et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 1986; 324:73-6.
26. Hirano T. Interleukin 6 and its receptor: ten years later. Int Rev Immunol 1998;16:249-84.
27. Salgado R, Junius S, Benoy I, et al. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer 2003; 103:642-6.
28. Culig Z, Bartsch G, Hobisch A. Interleukin-6 regulates androgen receptor activity and prostate cancer cell growth. Mol Cell Endocrinol 2002; 197:231-8.
29. Plante M, Rubin SC, Wong GY, et al. Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. Cancer 1994; 73:1882-8.
30. Tempfer C, Zeisler H, Sliutz G, et al. Serum evaluation of inter-leukin 6 in ovarian cancer patients. Gynecol Oncol 1997; 66: 27-30.
31. Moretti S, Chiarugi A, Semplici F, et al. Serum imbalance of cytokines in melanoma patients. Melanoma Res 2001; 11: 395-9.
32. Jee SH, Shen SC, Chiu HC, et al. Overexpression of interleu-kin-6 in human basal cell carcinoma cell lines increases anti-apoptotic activity and tumorigenic potency. Oncogene 2001; 20:198-208.
33. Su J, Kai K, Chen C, et al. A novel peptide specifically binding to interleukin-6 receptor (gp80) inhibits angiogenesis and tumor growth. Cancer Res 2005; 65:4827-35.
34. th edition. Philadelphia, PA: Lippincott & Wilkins, 2005: 129-137.
35. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004; 54:8-29.
36. Li D, Xie K, Wolff R, et al. Pancreatic cancer. Lancet 2004; 363:1049-57.
37. Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15:2403-13.
38. Abbruzzese JL. New application of gemcitabine and future directions in the management of pancreatic cancer. Cancer 2002; 95:941-5.
39. Perugini RA, McDade TP, Vittimberga FJ, et al. Pancreatic cancer cell proliferation is phosphatidylinositol 3-kinase dependent. J Surg Res 2000; 90:29-44.
40. Nicholson KM, Anderson NG. The protein kinase B/Akt signaling pathway in human malignancy. Cell Signal 2002; 14: 381-95.
41. Wang W, Abbruzzese JL, Evans DB, et al. The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 1999; 5:119-27.
42. Douziech N, Calvo E, Laine J, et al. Activation of MAP kinases in growth responsive pancreatic cancer cells. Cell Signal 1999; 11:591-602.
43. Ghaneh P, Kawesha A, Evans JD, et al. Molecular prognostic markers in pancreatic cancer. J Hepatobiliary Pancreat Surg 2002; 9:1-11.
44. Kuwahara K, Sasaki T, Kuwada Y, et al. Expressions of angio-genic factors in pancreatic ductal carcinoma: a correlative study with clinico-pathologic parameters and patient survival. Pancreas 2003; 26:344-9.
45. Yamanaka Y, Friess H, Kobrin MS, et al. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res 1993; 13:565-9.
46. Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 1999; 5:1359-64.
47. Gerber HP, Dixit V, Ferrara N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem 1998; 273:13313-6.
48. Tran J, Rak J, Sheehan C, et al. Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. Biochem Biophys Res Commun 1999; 264:781-8.
49. Kim SJ, Uehara H, Yazici S, et al. Modulation of bone microenvironment with Zoledronate enhances the therapeutic effects of STI571 and Paclitaxel against experimental bone metastasis of human prostate cancer. Cancer Res 2005; 65:3707-15.
50. Ebert M, Yokoyama M, Friess H, et al. Induction of platelet-derived growth factor A and B chains and over-expression of their receptors in human pancreatic cancer. Int J Cancer 1995; 62:529-35.
51. Hwang RF, Yokoi K, Bucana CD, et al. Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model. Clin Cancer Res 2003; 9:6534-44.
52. Ostman A. PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cyto-kine Growth Factor Rev 2004; 15(4):275-86.
53. Heldin C-H, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999; 79: 1283-316.
54. Bergers G, Song S, Meyer-Morse N, et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003; 111(9):1287-95.
55. Pietras K, Rubin K, Sjoblom T, et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 2002; 62:5476-84.
56. Pietras K. Increasing tumor uptake of anticancer drugs with imatinib. Semin Oncol 2004; 31:18-23.
57. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295:139-45.
58. Traxler P, Allegrini PR, Brandt R, et al. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res 2004; 64:4931-41.
59. Yokoi K, Sasaki T, Bucana CD, et al. Simultaneous inhibition of EGF-R, VEGF-R, and PDGF-R signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model. Cancer Res 2005; 65:10371-80.
60. Gerber HP, McMurtrey A, Kowalski J, et al. Vascular endothe-lial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 1998; 273:30336-43.
61. Hobson B, Denekamp J. Endothelial proliferation in tumours and normal tissues: continuous labeling studies. Br J Cancer 1984;49:405-13.
62. Eberhard A, Kahlert S, Goede V, et al. Heterogeneity of angio-genesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 2000; 60:1388-93.
63. Weber KL, Doucet M, Price JE, et al. Blockade of epidermal growth factor-receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mice. Cancer Res 2003; 63: 2940-7.
64. Kedar D, Baker CH, Killion JJ, et al. Blockade of the epidermal growth factor receptor signaling inhibits angiogenesis leading to the regression of human renal cell carcinoma growing ortho-topically in nude mice. Clin Cancer Res 2002; 8:3592-3600.
65. Traxler P, Buchdunger E, Furet P, et al. Preclinical profile of PKI166-a novel and potent EGF-R tyrosine kinase inhibitor for clinical development. Clin Cancer Res 1999; 5:3750-8.
66. Baker CH, Kedar D, McCarty MF, et al. Blockade of epidermal growth factor receptor signaling on tumor cells and tumor-associated endothelial cells for therapy of human carcinomas. Am J Pathol 2002; 161:929-38.
67. Baker CH, Pino MS, Fidler IJ. Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells in human renal cell carcinoma is a primary target for therapy by tyrosine kinase inhibitors. Neoplasia 2006; 8: 470-6.
68. Saltz L, Rubin M, Hochster H, et al. Cetuximab (IMC-225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer that expresses epidermal growth factor receptors. Proc Am Soc Clin Oncol 2001; 20:3-7.
69. Moasser MM, Basso A, Averbuch SD, et al. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 2001; 61:7184-8.
70. Solorzano CC, Baker CH, Tsan R, et al. Optimization for the blockade of epidermal growth factor receptor signaling for therapy of human pancreatic carcinoma. Clin Cancer Res 2001; 7:2563-72.
71. Rak J, Filmus J, Kerbel RS. Reciprocal paracrine interactions between tumor cells and endothelial cells: the 'angiogenesis progression' hypothesis. Eur J Cancer 1996; 32A:2438-50.
72. Yoneda J, Kuniyasu H, Crispens MA, et al. Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J Natl Cancer Inst 1998; 90:447-54.
73. Radinsky R, Risin S, Fan D, et al. Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clin Cancer Res 1995; 1:19-31.
74. Albanell J, Rojo F, Averbuch S, et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002; 20:110-24.
75. Baselga J, Rischin D, Ranson M, et al. Phase I safety, pharma-cokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002; 20:4292-302.
76. Sirotnak FM, Zakowski MF, Miller VA, et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGF-R tyrosine kinase. Clin Cancer Res 2000; 6:4885-92.
77. Ciardiello F, Caputo R, Bianco R, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000; 6:2053-63.
78. Hirata A, Uehara H, Izumi K, et al. Direct inhibition of EGF receptor activation in vascular endothelial cells by gefitinib ("Iressa", ZD 1839). Cancer Sci 2004; 95:614-8.
79. Naito S, Walker SM, Fidler IJ. In vivo selection of human renal cell carcinoma cells with high metastatic potential in nude mice. Clin Exp Metastasis 1989; 7:381-9.
80. Landis SH, Murray T, Bolden-Wingo PA. Cancer statistics, 1999. Cancer 1999; 49:8-31.
81. Soh S, Kattan MW, Berkman S, et al. Has there been a recent shift in the pathological features and prognosis of patients treated with radical prostatectomy? J Urol 1997; 157:2212-8.
82. Barrettoni BA, Carter JR. Mechanisms of cancer metastasis to bone. J Bone Joint Surg Am 1986; 68A:308-12.
83. Jacobs SC. Spread of prostatic cancer to bone. Urology 1983; 21:337-44.
84. Huggins C, Hodges CV. Studies on prostate cancer: The effects of castration on advanced carcinoma of the prostate (abstr). Arch Surg 1941; 43:209.
85. Byar DP, Corle DK. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monograph 1988; 7:165-70.
86. Millikan R, Thall PF, Lee SJ, et al. Randomized multicenter phase II trial of two multicomponent regimens in androgen-independent prostate cancer. J Clin Oncol 2003; 21:878-83.
87. Smith DC, Esper P, Strawderman M, et al. Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. J Clin Oncol 1999; 17: 1664-71.
88. Kim SJ, Uehara H, Yazici S, et al. Simultaneous blockade of platelet-derived growth factor-receptor and epidermal growth factor-receptor signaling and systemic administration of pacli-taxel as therapy for human prostate cancer metastasis in bone of nude mice. Cancer Res 2004; 64:4201-4208.
89. Yazici S, Kim SJ, Busby JE, et al. Dual inhibition of the epidermal growth factor and vascular endothelial growth factor phosphorylation for antivascular therapy of human prostate cancer in the prostate of nude mice. Prostate 2005; 65:203-15.
90. Klement G, Baruchel S, Rak J, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000; 105:R15-R24.
91. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl-positive cells. Nat Med 1996; 2:561-5.
92. Uehara H, Kim SJ, Karashima T, et al. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of prostate cancer bone metastasis. J Natl Cancer Inst 2003; 95:458-70.
93. Kim SJ, Uehara H, Karashima T, et al. Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice. Clin Cancer Res 2003; 9:1200-10.
94. Bruns CJ, Solorzano CC, Harbison MT, et al. Blockade of the epidermal growth factor receptor signaling by a novel tyro-sine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 2000;60:2926-35.
95. Hou X, Johnson AC, Rosner MR. Induction of epidermal growth factor receptor gene transcription by transforming growth factor beta 1: association with loss of protein binding to a negative regulatory element. Cell Growth Differ 1994; 5:801-9.
96. Saha D, Datta PK, Sheng H, et al. Synergistic induction of cyclo-oxygenase-2 by transforming growth factor-β1 and epidermal growth factor inhibits apoptosis in epithelial cells. Neoplasia 1999; 1:508-17.
97. Vinals F, Pouyssegur J. Transforming growth factor (TGF)-β1 promotes endothelial cell survival during in vitro angiogenesis via an autocrine mechanism implicating TGF-α signaling. Mol Cell Biol 2001; 21:7218-30.
98. Soory M, Virdi H. Implications of minocycline, platelet-derived growth factor, and transforming growth factor-β on inflammatory repair potential in the periodontium. J Periodontol 1999; 70:1136-43.
99. Seifert RA, Coats SA, Raines EW, et al. Platelet-derived growth factor (PDGF)-receptor α-subunit mutant and reconstituted cell lines demonstrate that transforming growth factor-β can be mitogenic through PDGF A-chain-dependent and-independent pathways. J Biol Chem 1994; 269:13951-5.
100. Lorenzo GD, Tortora G, D'Armiento FP, et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin. Cancer Res 2002; 8:3438-44.
101. Fudge K, Bostwick DG, Stearns ME. Platelet-derived growth factor A and B chains and α and β receptors in prostatic intraep-ithelial neoplasia. Prostate 1996; 29:282-6.
102. Levitzki A. Tyrosine kinases as targets for cancer therapy. Eur J Cancer 2002; 38(suppl 5): S11-8.
103. Capdeville R, Buchdunger E, Zimmermann J, et al. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002; 1:493-502.
104. Manley PW, Cowan-Jacob SW, Buchdunger E, et al. Imatinib: a selective tyrosine kinase inhibitor. Eur J Cancer 2002; 38(suppl 5):S19-27.
105. Ulrich A, Coussens L, Hayflick JS, et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature (Lond) 1984; 309:418-25.
106. Ciardiello F, Damiano V, Bianco R, et al. Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. J Natl Cancer Inst 1996; 88:1770-6.
107. Uckun FM, Narla RK, Zeren T, et al. In vivo toxicity, pharmacokinetics, and anticancer activity of Genistein linked to recombinant human epidermal growth factor. Clin Cancer Res 1988; 4:1125-34.
108. Uckun FM, Narla RK, Jun X, et al. Cytotoxic activity of epidermal growth factor-genistein against breast cancer cells. Clin. Cancer Res 1988; 4:901-12.
109. Thyberg J. The microtubular cytoskeleton and the initiation of DNA synthesis. Exp Cell Res 1984; 155:1-8.
110. Yoon S Y, Tefferi A, Li CY. Cellular distribution of platelet-derived growth factor, transforming growth factor-β, basic fibroblast growth factor, and their receptors in normal bone marrow. Acta Haematol 2000; 104:151-7.
111. Saharinen P, Alitalio K. Double target for tumor mass destruction. J Clin Invest 2003; 111:1277-80.
112. Mathew P, Fidler IJ, Logothetis CJ. Combination Docetaxel and platelet derived growth factor receptor inhibition with imatinib mesylate in prostate cancer. Semin. Oncol 2004; 31:24-9.
113. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62:385-427.
114. Van Brussel JP, Jan Van Steenbrugge G, Van Krimpen C, et al. Expression of multidrug resistance related proteins and prolif-erative activity is increased in advanced clinical prostate cancer. J Urol 2001; 165:130-5.
115. Kerbel RS, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002; 2:727-39.
116. Preise D, Mazor O, Koudinova N, et al. Bypass of tumor drug resistance by antivascular therapy. Neoplasia 2003; 5:475-80.
117. Kim SJ, Uehara H, Yazici S, et al. Targeting platelet-derived growth factor receptor on endothelial cells of multidrug resistant prostate cancer. J Natl Cancer Inst 2006; 98:783-93.